Literature DB >> 24681218

Differential T-cell responses of semi-immune and susceptible malaria subjects to in silico predicted and synthetic peptides of Plasmodium falciparum.

Jerome Nyhalah Dinga1, Stanley Kimbung Mbandi2, Fidelis Cho-Ngwa3, Nde Peter Fon4, Johnson Moliki5, Rose Mary Efeti6, Babila Raymond Nyasa7, Damian Nota Anong8, Nebojsa Jojic9, David Heckerman10, Ruobing Wang11, Vincent P K Titanji12.   

Abstract

Malaria remains a public health hazard in tropical countries as a consequence of the rise and spread of drug and insecticide resistances; hence the need for a vaccine with widespread application. Protective immunity to malaria is known to be mediated by both antibody and cellular immune responses, though characterization of the latter has been less extensive. The aim of the present investigation was to identify novel T-cell epitopes that may contribute to naturally acquired immune responses against malaria. Using the Microsoft software, Epitome™ T-cell peptide epitopes on 19 Plasmodium falciparum proteins in the Plasmodium Database (www.plasmodb.org.PlasmoDB 9.0) were predicted in-silico. The peptides were synthesized and used to stimulate peripheral blood mononuclear cells (PBMCs) in 14 semi-immune and 21 malaria susceptible subjects for interferon-gamma (IFN-γ) production ex-vivo. The level of IFN-γ production, a marker of T-cell responses, was measured by ELISPOT assay in semi-immune subjects (SIS) and frequently sick subjects (FSS) from an endemic zone with perennial malaria transmission. Of the 19 proteins studied, 17 yielded 27 pools (189 peptides), which were reactive with the subjects' PBMCs when tested for IFN-γ production, taking a stimulation index (SI) of ≥2 as a cutoff point for a positive response. There were 10 reactive peptide pools (constituting eight protein loci) with an SI of 10 or greater. Of the 19 proteins studied, two were known vaccine candidates (MSP-8 and SSP2/TRAP), which reacted both with SIS and FSS. Similarly the hypothetical proteins (PFF1030w, PFE0795c, PFD0880w, PFC0065c and PF10_0052) also reacted strongly with both SIS and FSS making them attractive for further characterization as mediators of protective immunity and/or pathogenesis.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ELISPOT; Interferon-gamma; Malaria; T-cell epitope; Vaccine

Mesh:

Substances:

Year:  2014        PMID: 24681218     DOI: 10.1016/j.actatropica.2014.03.007

Source DB:  PubMed          Journal:  Acta Trop        ISSN: 0001-706X            Impact factor:   3.112


  3 in total

1.  Preclinical efficacy and immunogenicity assessment to show that a chimeric Plasmodium falciparum UB05-09 antigen could be a malaria vaccine candidate.

Authors:  J N Dinga; S D Gamua; S M Ghogomu; V P K Titanji
Journal:  Parasite Immunol       Date:  2018-01-25       Impact factor: 2.280

2.  Enhanced acquired antibodies to a chimeric Plasmodium falciparum antigen; UB05-09 is associated with protective immunity against malaria.

Authors:  J N Dinga; S D Gamua; V P K Titanji
Journal:  Parasite Immunol       Date:  2017-06-22       Impact factor: 2.280

3.  Analysis of the Role of TpUB05 Antigen from Theileria parva in Immune Responses to Malaria in Humans Compared to Its Homologue in Plasmodium falciparum the UB05 Antigen.

Authors:  Jerome Nyhalah Dinga; Stephanie Numenyi Perimbie; Stanley Dobgima Gamua; Francis N G Chuma; Dieudonné Lemuh Njimoh; Appolinaire Djikeng; Roger Pelle; Vincent P K Titanji
Journal:  Pathogens       Date:  2020-04-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.